<DOC>
	<DOCNO>NCT02718326</DOCNO>
	<brief_summary>The primary objective study assess efficacy intravitreal ( IVT ) aflibercept compare sham treatment improvement moderately severe severe nonproliferative diabetic retinopathy ( NPDR ) .</brief_summary>
	<brief_title>Study Efficacy Safety Intravitreal ( IVT ) Aflibercept Improvement Moderately Severe Severe Nonproliferative Diabetic Retinopathy ( NPDR )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>Key 1 . Men woman ≥18 year age type 1 2 diabetes mellitus moderately severe severe NPDR ( DRSS level 47 53 ) , confirmed central reading center , PRP safely defer least 6 month per investigator 2 . BCVA ETDRS letter score study eye ≥69 letter ( approximate Snellen equivalent 20/40 good ) Key 1 . Presence DME threaten center macula study eye 2 . Evidence retinal neovascularization clinical examination Fluorescein Angiography ( FA ) 3 . Any prior focal grid laser photocoagulation prior PRP study eye 4 . Any prior systemic antiVEGF treatment IVT antiVEGF treatment study eye 5 . Any prior intraocular steroid injection study eye 6 . Current anterior segment neovascularization ( ASNV ) , vitreous hemorrhage , tractional retinal detachment visible screen assessment study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>